Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $120.81M.
ENTERPRISE VALUE (EV)
$120.81M
Inhibikase Therapeutics, Inc.
Market Cap
$260.03M
Enterprise Value (EV)
$120.81M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | $260.03M | $120.81M |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $260.47M | $209.99M |
| AC Immune S.A. (ACIU)vs › | $259.01M | $229.75M |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.42M | $174.33M |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.28M | $241.19M |
| Century Therapeutics, Inc. (IPSC)vs › | $255.24M | $240.23M |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $252.78M | $166.76M |
| Fate Therapeutics, Inc. (FATE)vs › | $272.65M | $315.90M |
| Indaptus Therapeutics, Inc. (INDP)vs › | $272.91M | $265.36M |
| Aurora Cannabis Inc. (ACB)vs › | $275.95M | $208.54M |
Market Cap
$260.03M
Total Debt
$0.00
Cash
$139.22M
Enterprise Value
$120.81M
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Why use EV instead of Market Cap?
